

Published in final edited form as:

*Br J Haematol.* 2005 October ; 131(1): 129–134.

## Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease

Charles T. Quinn<sup>1,2,3</sup> and Naveed Ahmad<sup>3</sup>

<sup>1</sup> Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA

<sup>2</sup> Southwestern Comprehensive Sickle Cell Center, Dallas, TX, USA

<sup>3</sup> Children's Medical Center Dallas, Dallas, TX, USA

### Summary

Individuals with sickle cell disease (SCD) may have oxyhaemoglobin desaturation during the steady-state, the causes of which are incompletely known. We studied a cohort of 585 children who have sickle cell anaemia (SS), sickle  $\beta^0$ -thalassaemia ( $S\beta^0$ ), sickle-haemoglobin C disease (SC), or sickle  $\beta^+$ -thalassaemia ( $S\beta^+$ ) to determine the relationships between steady-state oxyhaemoglobin saturation ( $SpO_2$ ) and SCD genotype, age, gender, steady-state haemoglobin (Hb) and reticulocyte count, and rate of acute chest syndrome (ACS). The SS/ $S\beta^0$  group ( $n = 390$ ) had lower mean  $SpO_2$  than the SC/ $S\beta^+$  group ( $n = 195$ ) (96.3% vs. 98.7%,  $P < 0.001$ ). Among SS/ $S\beta^0$  subjects, a decrease in steady-state  $SpO_2$  correlated with a decrease in Hb, an increase in reticulocytes, older age and male gender. These correlations were not found in the SC/ $S\beta^+$  group. Prior ACS did not correlate with steady-state  $SpO_2$ . A multivariate model explained 45% of the variability in  $SpO_2$ , but only 5% of the variation in  $SpO_2$  was explained by Hb. We conclude that steady-state desaturation is common in individuals with SCD, but it appears to be unrelated to prior episodes of ACS and largely unexplained by chronic anaemia.

### Keywords

sickle cell disease; pulse oximetry; hypoxaemia; children

Many individuals with sickle cell disease (SCD) have arterial oxyhaemoglobin desaturation during the steady-state in the absence of overt cardiopulmonary illness (Homi *et al*, 1997). Steady-state desaturation in SCD is partly caused by a rightward shift of the oxyhaemoglobin dissociation curve because of the properties of sickle haemoglobin (Hb S) in solution (Seakins *et al*, 1973; Ueda *et al*, 1979) and the effects of chronic anaemia mediated through 2,3-bisphosphoglycerate (Milner, 1974). Desaturation is not a universal finding among individuals who have homozygous sickle cell anaemia (SS), however, and the causes of inter-patient variability are incompletely known.

Prior studies have consistently shown a direct correlation between steady-state haemoglobin (Hb) concentration and steady-state oxyhaemoglobin saturation measured by pulse oximetry ( $SpO_2$ ) (Rackoff *et al*, 1993; Homi *et al*, 1997; Setty *et al*, 2003). Past studies also concur that  $SpO_2$  is lower, on average, among individuals who have SS compared with those who have sickle-haemoglobin C disease (SC) (Rackoff *et al*, 1993; Homi *et al*, 1997; Setty *et al*, 2003). Another cause of steady-state desaturation could be chronic cardiopulmonary disease caused

by recurrent episodes of acute chest syndrome (ACS), yet prior studies provide contradictory evidence for such an association (Rackoff *et al*, 1993; Homi *et al*, 1997). Reported correlations between SpO<sub>2</sub> and age, gender, and reticulocyte count have also been contradictory or not corroborated by all investigators (Rackoff *et al*, 1993; Homi *et al*, 1997; Setty *et al*, 2003).

Therefore, we aimed to resolve the discrepancies in the literature by using multivariable statistical techniques in a large cohort of children with SCD. We developed a model to determine the relative contributions to steady-state SpO<sub>2</sub> of multiple factors, namely a history of ACS, steady-state Hb, steady-state reticulocyte count, age, gender and SCD genotype. We hypothesised that steady-state Hb concentration did not explain most of the variation in SpO<sub>2</sub> and that a history of ACS could explain some of this variability.

## Patients and methods

This study is a retrospective analysis of our centre's existing comprehensive SCD database. We identified every subject in this database who: (i) was less than 20 years of age; (ii) had a diagnosis of either SS, SC, sickle- $\beta^+$ -thalassaemia (S $\beta^+$ ), or sickle- $\beta^0$ -thalassaemia (S $\beta^0$ ); (iii) had at least one outpatient clinical evaluation during the preceding 5 years; and (iv) had a documented steady-state Hb concentration, reticulocyte count (%), and SpO<sub>2</sub>. The Institutional Review Board of UT Southwestern Medical Center approved the use of the database for this project. The majority of these subjects were members of the previously described Dallas Newborn Cohort (Quinn *et al*, 2004). Individuals who were currently receiving chronic red blood cell transfusions were excluded from the analysis. All steady-state values were calculated as rolling averages of at least three measurements obtained during routine 'well' or 'steadystate' clinic visits. Steady-state SpO<sub>2</sub> was measured in room air by trained nurses and technicians using the Nellcor N-395 pulse oximeter (Nellcor Puritan Bennett Inc., Pleasanton, CA, USA).

We searched the database for the clinical diagnoses, 'acute chest syndrome', 'pneumonia' and abbreviations or permutations thereof that were recorded at the time of the events. In our clinical practice, we defined ACS as an acute pulmonary illness in a person who has SCD that is characterised by a new radiographic pulmonary infiltrate and some combination of fever, hypoxaemia, thoracic pain, and signs and symptoms of respiratory illness. Lifetime rates of ACS were calculated for a large subset of subjects with SS and S $\beta^0$  ( $n = 183$ ). This subset included only the children who were  $\geq 5$  years of age, and rates were calculated using only episodes of ACS that occurred after the third birthday. This level of stringency was used because ACS in the infant or very young child is typically mild, transient and related to viral respiratory infections (Vichinsky *et al*, 1997, 2000). The period of follow-up for the rate calculation was the interval between the third birthday and the last documented clinical encounter or the date of initiation of a disease-modifying therapy (hydroxyurea or stem cell transplantation). Thus, all rates were calculated for a minimum of 2 years of follow-up in children who were 5 years of age or older.

We combined subjects into two groups for study: (i) SS or S $\beta^0$  and (ii) SC or S $\beta^+$ . We combined the genotypes in this way because of the known clinical similarity of the grouped diseases, the very small number in the S $\beta^0$  subgroup ( $n = 9$ ), and because exploratory analyses showed the subjects within each group to be similar. For descriptive statistics, we calculated mean values, standard deviations and frequency histograms for continuous variables and proportions for categorical variables. We used the *t*-test, chi-squared test or Fisher's exact test, where appropriate, to compare groups of subjects (SS/S $\beta^0$  vs. SC/S $\beta^+$ ; male vs. female). Steady-state SpO<sub>2</sub> was defined as the dependent variable and steady-state Hb, steady-state reticulocyte count, age, gender, SCD genotype and ACS rate as independent or potential predictor variables. Pearson correlation was used to investigate relationships between SpO<sub>2</sub> and the potential

predictor variables and to assess for multi-collinearity between variables. Independent variables for multivariate (regression) analysis were selected based on clinical importance and statistical significance found by bivariate analyses. A linear regression model was used to determine the significant predictors of steady-state SpO<sub>2</sub> and their adjusted associations. Partial correlation coefficients were computed to describe the linear relationship between SpO<sub>2</sub> and Hb while controlling for the effects of other variables simultaneously. All data were analysed using spss 11.0 statistical software (SPSS Inc., Chicago, IL, USA). *P*-values <0.05 were considered significant.

## Results

### Descriptive and bivariate analysis

There were 585 subjects for analysis (Table I). Fig 1 depicts the distributions of steady-state SpO<sub>2</sub> by SCD genotype. The results of bivariate analyses are presented in Table II and Fig 2. Among SS/Sβ<sup>0</sup> subjects, there were significant correlations between SpO<sub>2</sub> and Hb (Fig 2, panel A), reticulocyte count and age (Fig 2, panel C). On the contrary, none of these correlations was found to be significant among SC/Sβ<sup>+</sup> subjects (Table II; Fig 2, Panel B). Among the subset of subjects with SS/Sβ<sup>0</sup> whose lifetime ACS rates were calculated, no significant correlation was found between ACS rate and SpO<sub>2</sub> (Fig 2, panel D). The mean SpO<sub>2</sub> of SS/Sβ<sup>0</sup> males was lower than females (96.0% vs. 96.7%, *P* = 0.014), while the SpO<sub>2</sub> of SC/Sβ<sup>+</sup> subjects did not differ significantly between genders (*P* = 0.770).

### Multivariate analysis

After testing for the required assumptions, standard multiple regression analysis was performed between SpO<sub>2</sub> as the dependent variable, and Hb, age, gender, and the reticulocyte count as independent variables (Table III). The residual analysis suggested that the distribution was reasonably close to normal, linear and homoscedastic. ACS rate was not included in the model as an independent variable because of a lack of linear relationship with the outcome variable. Both Hb and reticulocyte count were included as independent variables in the model because they did not correlate strongly enough with each other to qualify for the multi-collinearity assumption (*R* = -0.587).

The multivariate analysis performed on SC/Sβ<sup>+</sup> subjects did not yield any significant results (Table III). Among SS/Sβ<sup>0</sup> subjects, all four of the independent variables contributed significantly to prediction of SpO<sub>2</sub> (Table III). A multiple correlation coefficient (*R* = 0.67) showed a significant linear relationship between independent variables and steady-state SpO<sub>2</sub> (*F* = 78.07, *P* < 0.001). The estimated model for SS/Sβ<sup>0</sup> subjects could be given as:

$$\begin{aligned} \text{SpO}_2 = & 94.24 + (0.58 \times \text{Hb}) - (0.16 \times \text{age in years}) \\ & + (0.64 \times \text{gender}) - (0.20 \times \text{reticulocyte count in \%}). \end{aligned}$$

Considering 'gender' in the equation, females were assigned a value of 1 and males a value of 0; thus, the multivariate model estimated that females, on average, had an SpO<sub>2</sub> that was 0.64% higher (absolute increase) than males. This small difference between males and females was statistically significant in both bivariate (*P* = 0.014) and multivariate (*P* = 0.006) analyses.

In summary, among SS/Sβ<sup>0</sup> subjects, a decrease in steady-state SpO<sub>2</sub> was related to a decrease in Hb concentration, increase in reticulocyte count, older age, and male gender. Altogether, about 45% (adjusted 44%) of the variability in SpO<sub>2</sub> could be explained by these independent variables in the model. Notably, only 5% of the variation in SpO<sub>2</sub> was explained by Hb while controlling for other variables (Table III).

## Discussion

In this largest study to date of pulse oximetry measurements in a cohort of children with SCD, we showed that steady-state desaturation is common among individuals who have SS or S $\beta^0$  and relatively uncommon among those who have SC or S $\beta^+$ , consistent with prior studies (Rackoff *et al*, 1993; Homi *et al*, 1997; Setty *et al*, 2003). We also confirmed the observation of a direct relationship between Hb and SpO<sub>2</sub> (Homi *et al*, 1997; Setty *et al*, 2003). However, we clearly showed that only 5% of the variation in steady-state SpO<sub>2</sub> of subjects with SS or S $\beta^0$  is explained by steady-state Hb concentration alone. This new observation indicates that the effects of chronic anaemia do not primarily explain steady-state desaturation in SCD. Setty *et al* 2003 found a correlation between SpO<sub>2</sub> and reticulocytosis. Likewise, we have now shown that 12% of the variation in SpO<sub>2</sub> is explained by the reticulocyte count. Hb and reticulocyte count inversely correlated with each other, of course, although not strongly enough in this analysis to qualify for the multicollinearity assumption. Thus, reticulocytosis exerts an effect on SpO<sub>2</sub> independent of Hb concentration, perhaps indicating a difference in the shapes of the oxyhaemoglobin dissociation curves between Hb within reticulocytes and Hb within mature erythrocytes.

Another possible explanation for steady-state desaturation is subclinical or chronic cardiopulmonary disease. Recurrent episodes of ACS have been associated with chronic lung disease (Powars *et al*, 1988). As such, steady-state desaturation might be an indicator of pulmonary injury, and individuals who have suffered more frequent episodes of ACS might be expected to be more hypoxaemic in the steady-state. Rackoff *et al* 1993 studied 86 children with SS and found that a history of ACS was associated with desaturation after the age of 5 years; however, Homi *et al* 1997 studied 220 children with SS and found no association between ACS and SpO<sub>2</sub> after correction for Hb. We have shown here, in 183 subjects that the rate of ACS, at least during childhood, is not associated with SpO<sub>2</sub> (Fig 2, panel D). Thus, reasons other than cumulative ACS-related pulmonary injury must explain steady-state desaturation. This conclusion may be limited because it is possible that the rate of ACS is an insensitive predictor of chronic lung disease, and rather that the age of onset or the severity of individual episodes of ACS might be fundamental. We did not test this hypothesis because no reliable instruments to grade the severity of ACS have been reported. Also, because we studied episodes of ACS that were diagnosed according to the expert clinical practice at a single centre and not a protocolspecific definition, the ascertainment of ACS cases may have been incomplete or inaccurate. However, the crude incidence of ACS in this study, 18.4 episodes per 100 patient-years, is similar to the overall incidence of 12.8 per 100 patients reported for SS patients in the Cooperative Study of Sickle Cell Disease (Castro *et al*, 1994).

Here, we demonstrated that males are more likely to have a lower SpO<sub>2</sub> than females, a finding not reported in past studies (Rackoff *et al*, 1993; Homi *et al*, 1997; Setty *et al*, 2003). The effect of gender on SpO<sub>2</sub> was small and probably not clinically significant, but the difference was statistically significant in both bivariate ( $P = 0.014$ ) and multivariate analysis ( $P = 0.006$ ). Although the frequency of some complications of SCD may differ between sexes, we did not investigate any potential biological explanations for this interesting finding.

We also showed that the degree of steady-state desaturation increased with age. Much of the age-related decline in SpO<sub>2</sub> occurs in the first 5 years of life (Fig 2, panel C). Because foetal Hb (Hb F) has higher O<sub>2</sub> affinity than Hb S, and because the decline of Hb F to its steady-state level may take 2–5 years (Serjeant & Serjeant, 2001), the effect of age on SpO<sub>2</sub> could be explained by the normal developmental decline in Hb F concentration. Indeed, Rackoff *et al* 1993 found a similar association with age, but it was not significant when Hb F was also included in the model. We did not systematically measure the Hb F level in our subjects to test this hypothesis, but there was no statistically significant association between SpO<sub>2</sub> and age

among children 5 years of age and older (data not shown). Other investigators (Homi *et al*, 1997; Setty *et al*, 2003) found no association between age and SpO<sub>2</sub>, perhaps because they studied individuals with SCD who were 9–18 and 3–19 years of age, respectively, and did not include the youngest children in whom we found the strongest correlation with age.

It is tempting to speculate that slowly worsening steady-state desaturation could be a marker of developing pulmonary hypertension, which is increasingly recognised as a common and life-threatening complication of young adults with SS (Gladwin *et al*, 2004). The development of pulmonary hypertension is thought to be related to the degree of haemolysis and secondary endothelial dysfunction (Morris *et al*, 2005). We found that both Hb and reticulocyte count, indicators of haemolysis, were associated with desaturation, but we did not investigate any relationship between pulmonary hypertension and desaturation in this study.

Whatever its cause, desaturation is increasingly recognised as a marker or predictor of certain vaso-occlusive complications of SCD. For example, nocturnal hypoxaemia is associated with higher rates of pain in childhood (Hargrave *et al*, 2003) and an increased likelihood of central nervous system events (strokes, transient ischemic attacks and seizures) in children and young adults (Kirkham *et al*, 2001). Setty *et al* 2003 studied biologic correlates of oxyhaemoglobin saturation to explain these associations (Setty *et al*, 2003). They found an inverse relationship between saturation and both the degree of erythrocyte–endothelial adhesion and the expression of markers of white blood cell, platelet and endothelial activation. Thus, desaturation may promote vaso-occlusive complications through hypoxia-mediated pathways. Several authors have suggested that screening for and appropriate management of nocturnal hypoxaemia might decrease the frequency of pain and stroke (Kirkham *et al*, 2001; Hargrave *et al*, 2003). It is not known whether daytime desaturation, studied here, has similar prognostic significance or if any intervention is needed.

It has long been assumed that cumulative ACS-related pulmonary injury and the effects of chronic anaemia on the oxyhaemoglobin dissociation curve are the causes of steady-state desaturation in SCD. Although we showed that steady-state Hb and SpO<sub>2</sub> were directly correlated, we found that only a small fraction (5%) of the variation in SpO<sub>2</sub> was explained by Hb concentration alone. Notably, we also demonstrated that past ACS is not associated with steady-state SpO<sub>2</sub>. Steady-state desaturation is clearly a complex phenomenon with multiple causes. Nevertheless, our multivariate model can explain nearly half of the variation in SpO<sub>2</sub>. This model provides mechanistic insights to steady-state desaturation and the ability to predict its occurrence in individuals who have SCD. Because of the association of hypoxaemia with vaso-occlusive complications, further study of the role of desaturation as a cause or consequence of SCD-related morbidity is needed.


#### Acknowledgements

We wish to thank Drs Zora R. Rogers and George R. Buchanan for their critical review of the manuscript. This work was supported by a grant from the National Institutes of Health (U54 HL 70588) (C.T.Q.).


#### References

- Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. *Blood* 1994;84:643–649. [PubMed: 7517723]
- Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *New England Journal of Medicine* 2004;350:886–895. [PubMed: 14985486]
- Hargrave DR, Wade A, Evans JP, Hewes DK, Kirkham FJ. Nocturnal oxygen saturation and painful sickle cell crises in children. *Blood* 2003;101:846–848. [PubMed: 12393400]

- Homi J, Levee L, Higgs D, Thomas P, Serjeant G. Pulse oximetry in a cohort study of sickle cell disease. *Clinical and Laboratory Haematology* 1997;19:17–22. [PubMed: 9146942]
- Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. *Lancet* 2001;357:1656–1659. [PubMed: 11425370]
- Milner PF. Oxygen transport in sickle cell anemia. *Archives of Internal Medicine* 1974;133:565–572. [PubMed: 4594394]
- Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA* 2005;294:81–90. [PubMed: 15998894]
- Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. *Medicine* 1988;67:66–76. [PubMed: 3336282]
- Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. *Blood* 2004;103:4023–4027. [PubMed: 14764527]
- Rackoff WR, Kunkel N, Silber JH, Asakura T, Ohene-Frempong K. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. *Blood* 1993;81:3422–3427. [PubMed: 7685205]
- Seakins M, Gibbs WN, Milner PF, Bertles JF. Erythrocyte Hb-S concentration. An important factor in the low oxygen affinity of blood in sickle cell anemia. *Journal of Clinical Investigation* 1973;52:422–432. [PubMed: 4683881]
- Serjeant, GR.; Serjeant, BE. *Sickle Cell Disease*. Oxford University Press; New York, NY: 2001.
- Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. *Lancet* 2003;362:1450–1455. [PubMed: 14602439]
- Ueda Y, Nagel RL, Bookchin RM. An increased Bohr effect in sickle cell anemia. *Blood* 1979;53:472–480. [PubMed: 32940]
- Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. *Cooperative Study of Sickle Cell Disease*. *Blood* 1997;89:1787–1792. [PubMed: 9057664]
- Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Mancini EA. Causes and outcomes of the acute chest syndrome in sickle cell disease. *National Acute Chest Syndrome Study Group*. *New England Journal of Medicine* 2000;342:1855–1865. [PubMed: 10861320]



**Fig 1.** Histograms of steady-state oxyhaemoglobin saturation, SpO<sub>2</sub> by sickle cell disease genotype. Panel (A) depicts subjects with either sickle cell anaemia or sickle β<sup>0</sup>-thalassaemia. Panel (B) depicts subjects with either sickle-haemoglobin C or sickle β<sup>+</sup>-thalassaemia.



**Fig 2.** Bivariate correlations between steady-state oxyhaemoglobin saturation (SpO<sub>2</sub>) and other variables by sickle cell disease genotypes. Panel (A) shows the correlation between Hb (Hgb) and SpO<sub>2</sub> among sickle cell anaemia (SS, grey circles) and sickle β<sup>0</sup>-thalassaemia (Sβ<sup>0</sup>, black squares) subjects. Panel (B) shows the correlation between Hb (Hgb) and SpO<sub>2</sub> among sickle haemoglobin C (grey circles) and sickle β<sup>+</sup>-thalassaemia (Sβ<sup>+</sup>, black squares) subjects. Panel (C) illustrates the correlation between SpO<sub>2</sub> and age among SS and Sβ<sup>0</sup> subjects. Panel (D) depicts the lack of correlation between SpO<sub>2</sub> and rate of acute chest syndrome among SS and Sβ<sup>0</sup> subjects.



**Table I**

Characteristics of subjects.

	SS/S $\beta^0$	SC/S $\beta^+$	P-value
Number	390	195	—
Number of males (%)	216 (55.4)	96 (49.2)	0.16
Mean age, years (SD)	9.5 (5.7)	9.2 (5.2)	0.476
Mean Hb, g/dl (SD)	8.2 (1.2)	10.7 (0.9)	<0.001
Mean SpO <sub>2</sub> in % (SD)	96.3 (3.0)	98.7 (1.7)	<0.001
Percentage with SpO <sub>2</sub> <96%	33.1	3.6	<0.001
Percentage with SpO <sub>2</sub> <90%	2.8	0.5	0.070

SS/S $\beta^0$ , sickle cell anaemia/sickle  $\beta^0$ -thalassaemia; SC/S $\beta^+$ , sickle-haemoglobin C/sickle  $\beta^+$ -thalassaemia; SpO<sub>2</sub>, steady-state oxyhaemoglobin saturation; SD, standard deviation.

**Table II**Bivariate correlations between SpO<sub>2</sub> and other variables by genotype.

	SS/Sβ <sup>0</sup>		SC/Sβ <sup>+</sup>	
	Pearson <i>R</i>	<i>P</i> -value	Pearson <i>R</i>	<i>P</i> -value
Steady-state Hb	0.517	<0.001	0.024	0.736
Age	-0.550	<0.001	-0.068	0.346
Reticulocyte count	-0.443	<0.001	-0.055	0.445
ACS rate	-0.043	0.559	—	—
	Mean SpO <sub>2</sub>	<i>P</i> -value	Mean SpO <sub>2</sub>	<i>P</i> -value
Gender (m/f)	95.99/96.74	0.014	98.67/98.74	0.770

SS/Sβ<sup>0</sup>, sickle cell anaemia/sickle β<sup>0</sup>-thalassaemia; SC/Sβ<sup>+</sup>, sickle-haemoglobin C/sickle β<sup>+</sup>-thalassaemia; SpO<sub>2</sub>, steady-state oxyhaemoglobin saturation; ACS, acute chest syndrome.

**Table III**Predictors of SpO<sub>2</sub> from standard multiple regression analysis by genotype.

	SS/Sβ <sup>0</sup>			SC/Sβ <sup>+</sup>		
	β	Partial R <sup>2</sup>	P-value	β	Partial R <sup>2</sup>	P-value
Intercept	94.244	—	<0.001	98.532	—	<0.001
Hb (g/dl)	0.584	0.053	<0.001	0.032	<0.001	0.837
Age (years)	-0.156	0.125	<0.001	-0.019	0.003	0.458
Gender (female)	0.643	0.019	0.006	0.125	0.001	0.615
Reticulocytes (%)	-0.196	0.122	<0.001	0.062	0.003	0.476
	<i>n</i> = 390, model R <sup>2</sup> = 0.448			<i>n</i> = 195, model R <sup>2</sup> = 0.009		